Neutropenia Market: Current Analysis and Forecast (2023-2030)
Emphasis on Type (Congenital Neutropenia, Febrile Neutropenia, Cyclic Neutropenia, Autoimmune Neutropenia, Others); Treatment (Antibiotic Therapy, Colony-Stimulating Factor Therapy, Granulocyte Transfusion, Others); End-Users (Hospitals, Homecare, Speciality Centres, Others); and Region/Country
The Neutropenia market was valued at USD 17329.2 million in 2022 & is expected to grow at a CAGR of 5.5% from 2023-2030. Neutropenia is a medical condition characterized by a low count of neutrophils; a type of white blood cell essential for the immune system. Neutropenia can result from various causes, including chemotherapy, certain medications, or underlying medical conditions. The market encompasses pharmaceutical interventions, therapeutic approaches, diagnostic tools, and supportive care aimed at addressing neutropenia and improving patient outcomes. The Growing prevalence of neutropenia induced by cancer treatments, particularly chemotherapy is boosting the neutropenia market. Cancer patients often experience neutropenia as a side effect, increasing the demand for therapeutic interventions to manage and prevent associated complications. For instance, according to PAHO, in 2023, Globally, there were an estimated 20 million new cases of cancer and 10 million deaths from cancer. The cancer burden will increase by approximately 60% over the next two decades, further straining health systems, people and communities.
Some of the major players operating in the market are Pfizer Inc., Novartis AG, AstraZeneca, Teva Pharmaceutical Industries Ltd., Mylan N.V, Sanofi , GSK plc , Merck & Co., Inc, Cipla Inc, Seagen, Inc. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.
Insights Presented in the Report
“Amongst type, the febrile neutropenia segment held a significant share of the market in 2023.”
Based on the type, the market has been categorized into congenital neutropenia, febrile neutropenia, cyclic neutropenia, autoimmune neutropenia and others. Among them, the febrile neutropenia segment is expected to grow at a higher CAGR in the market due to its association with increased vulnerability to infections, especially among individuals undergoing cancer treatments such as chemotherapy. Febrile neutropenia occurs when cancer patients with a low neutrophil count (neutropenia) develop a fever, which is often indicative of an underlying infection. Febrile neutropenia poses a significant risk of severe infections, and if not managed promptly and effectively, it can lead to life-threatening complications.
“Amongst treatment, the colony-stimulating factor therapy segment held the higher CAGR in the market in 2023.”
Based on the treatment, the market has been categorized into antibiotic therapy, colony-stimulating factor therapy, granulocyte transfusion, and others. Among them, the colony-stimulating factor therapy segment is expected to grow at a higher CAGR in the market. The colony-stimulating factor (CSF) therapy segment is crucial in the Neutropenia market because it plays a key role in managing neutropenia, particularly in cases where the condition is induced by chemotherapy or other medical treatments. Neutropenia is often a side effect of cancer treatments, and CSF therapy helps stimulate the production of neutrophils, a type of white blood cell, to reduce the risk of infections. This segment has witnessed growth due to the increasing prevalence of chemotherapy-induced neutropenia and the need for effective supportive care.
“North America dominated the Neutropenia market in 2023.”
The North America neutropenia market is expected to continue to grow in the coming years, driven by the increasing prevalence of cancer and growing awareness of neutropenia among healthcare professionals and the general population, development of advanced imaging techniques and the rise in treatment option. For instance, in 2020, according to American Cancer Society, Cancer is the second most common cause of death in the US, exceeded only by heart disease. around 609,360 deaths from cancer are expected in the US in 2022, which is about 1,670 deaths per day.
Neutropenia Market Report Coverage
Reasons to buy this report:
- The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
- The report presents a quick review of overall industry performance at one glance.
- The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolios, expansion strategies, and recent developments.
- Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
- The study comprehensively covers the market across different segments.
- Deep dive regional level analysis of the industry.
Customization Options:
The global Neutropenia market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.
Table of Contents
Research Methodology for the Neutropenia Market Analysis (2022-2030)
Analyzing the historical market, estimating the current market, and forecasting the future market of the global Neutropenia market were the three major steps undertaken to create and analyze the adoption of Neutropenia in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global Neutropenia market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry pertains to. Detailed methodology is explained below:
Analysis of Historical Market Size
Step 1: In-Depth Study of Secondary Sources:
Detail secondary study was conducted to obtain the historical market size of the Neutropenia market through company internal sources such as annual reports & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.
Step 2: Market Segmentation:
After obtaining the historical market size of the Neutropenia market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as type, treatment and end-users. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.
Step 3: Factor Analysis:
After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the Neutropenia market. Further, we conducted factor analysis using dependent and independent variables such as type, treatment and end-users of the Neutropenia market. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and product launches in the Neutropenia market sector across the globe.
Current Market Size Estimate & Forecast
Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global Neutropenia market, and market shares of the segments. All the required percentage shares split, and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.
Estimation & Forecasting: For market estimation and forecast, weights were assigned to different factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., the top-down/bottom-up approach were applied to arrive at the market forecast for 2030 for different segments and sub-segments across the major markets globally. The research methodology adopted to estimate the market size encompasses:
- The industry’s market size, in terms of revenue (USD) and the adoption rate of the Neutropenia market across the major markets domestically
- All percentage shares, splits, and breakdowns of market segments and sub-segments
- Key players in the global Neutropenia market in terms of products offered. Also, the growth strategies adopted by these players to compete in the fast-growing market
Market Size and Share Validation
Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.
Split of Primary Participants in Different Regions
Market Engineering
The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global Neutropenia market. data was split into several segments & sub-segments post studying various parameters and trends in the areas of the type, treatment and end-users in the global Neutropenia market.
The main objective of the Global Neutropenia Market Study
The current & future market trends of the global Neutropenia market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:
- Analyze the current and forecast market size of the Neutropenia market in terms of value (USD). Also, analyze the current and forecast market size of different segments and sub-segments
- Segments in the study include areas of the type, treatment and end-users
- Define and analysis of the regulatory framework for the Neutropenia industry
- Analyze the value chain involved with the presence of various intermediaries, along with analyzing customer and competitor behaviors of the industry
- Analyze the current and forecast market size of the Neutropenia market for the major region
- Major countries of regions studied in the report include Asia Pacific, Europe, North America, and the Rest of the World
- Company profiles of the Neutropenia market and the growth strategies adopted by the market players to sustain in the fast-growing market
- Deep dive regional level analysis of the industry
Frequently Asked Questions FAQs
Q1: What is the current market size and growth potential of the global Neutropenia market?
Q2: What are the driving factors for the growth of the global Neutropenia market?
Q3: Which segment will be the fastest growing segment of the global Neutropenia market by Type?
Q4: What are the emerging technologies and trends in the global Neutropenia market?
Q5: Which region will dominate the global Neutropenia market?
Q6: Who are the key players operating in the global Neutropenia market?
Related Reports
Customers who bought this item also bought
Antibiotic Resistance Market: Current Analysis and Forecast (2024-2032)
Emphasis on Disease Type (Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, And Others); Pathogen Type (Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and Others); Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others); and Region/Country
October 8, 2024
